{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092578","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.170555+00:00","generated_at":"2026-05-15T19:31:31.744507+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silence Therapeutics FY 2025 net loss $88.6M; top-line divesiran data on-track for Q3 2026","bullets":["Net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share) in FY 2024.","Collaboration revenue dropped to $0.6M from $43.3M; R&D spend flat at $67.8M.","Cash and investments $85.1M as of Dec 31, 2025; key Phase 2 SANRECO topline due Q3 2026.","AstraZeneca will not develop SLN312 beyond Phase 1; Silence regains global rights.","CEO search underway after former CEO departure in Dec 2025; Iain Ross interim."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092578","json":"https://secwatch.observer/filing/0001193125-26-092578.json","markdown":"https://secwatch.observer/filing/0001193125-26-092578.md","text":"https://secwatch.observer/filing/0001193125-26-092578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/0001193125-26-092578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/sln-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:31:31.744507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adf319cb83cfa932cc06e33a9ed41cc566206827","claim":"Silence Therapeutics plc reported the fourth quarter and full year ended December 31, 2025 results: revenue $0.6 million, net income $88.6 million, EPS $0.63 basic and diluted net loss per share.","evidence_excerpt":"Full Year 2025 Financial Results • Cash Position: Cash, cash equivalents, and short-term investments were $85.1 million as of December 31, 2025. This includes cash and cash equivalents of $11.3 million and short-term investments of $73.8 million. • Collaboration Revenue: Collaboration revenue was $0.6 million for the year ended December 31, 2025, compared to $43.3 million for the year ended December 31, 2024. The decrease for 2025 was primarily due to revenue associated with the Hansoh collaboration that concluded in 2024 and a $17.4 million decrease in revenue related to the AstraZeneca collaboration. • R&D Expenses: Research and development (R&D) expenses were $67.8 million for the year ended December 31, 2025, compared to $67.9 million for the year ended December 31, 2024. • G&A Expenses: General and administrative (G&A) expenses were $22.3 million for the year ended December 31, 2025, compared to $26.9 million for the year ended December 31, 2024. The decrease for 2025 was primaril","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/0001193125-26-092578-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$0.6 million"},{"label":"Net income","value":"$88.6 million"},{"label":"EPS","value":"$0.63 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}